Holding(s) in Company

RNS Number : 7960D
Circassia Pharmaceuticals Plc
01 April 2014
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Circassia Pharmaceuticals PLC

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights


X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):

 


 

3. Full name of person(s) subject to the notification obligation: iii

OppenheimerFunds, Inc.

4. Full name of shareholder(s)

(if different from 3.): iv


5. Date of the transaction and date on which the threshold is crossed or reached: v

28 March 2014

6. Date on which issuer notified:

31 March 2014

7. Threshold(s) that is/are crossed or

reached: vi, vii

5% (increased to 5.72%)

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00BJVD3B28

9,000,000

9,000,000

10,805,820


10,805,820


5.72%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion
Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

 

% of voting
rights






 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise
price

Expiration
date
xvii

Exercise/
Conversion
period
xviii

Number of voting
rights instrument
refers to

% of voting rights xix, xx

 






Nominal

Delta

 



 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

188,786,254

 

5.72%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

OppenheimerFunds, Inc. ("OFI") is a registered investment advisor with the U.S. SEC.  Its ultimate parent company, Massachusetts Mutual Life Insurance Company, qualifies for disaggregation under FCA regulations.  The shares of the issuer are held by investment accounts managed by OFI.

 

Proxy Voting:

10. Name of the proxy holder:


11. Number of voting rights proxy holder will cease to hold:


12. Date on which proxy holder will cease to hold voting rights:


 

13. Additional information:


14. Contact name:

Julien Cotta

Chief Financial Officer

15. Contact telephone number:

+44 (0) 1865 405560 



 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share


A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)


Contact address

(registered office for legal entities)


Phone number & email


Other useful information

(at least legal representative for legal persons)




B: Identity of the notifier, if applicable

Full name


Contact address


Phone number & email


Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)



C: Additional information


For notes on how to complete form TR-1 please see the FCA website.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUAONRSAASRAR

Companies

Niox Group (NIOX)
UK 100